Xilio Therapeutics (XLO) EBIT (2020 - 2026)
Xilio Therapeutics (XLO) posted EBIT of -$14.1 million for Q1 2026, down 19.23% sequentially from -$11.8 million in Q4 2025, and down 1.88% YoY from -$14.4 million in Q1 2025.
Xilio Therapeutics (XLO) EBIT (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported EBIT for 7 years, with the latest figure at -$14.1 million in Q1 2026.
- Quarterly EBIT fell 1.88% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.2 million (up 25.82% YoY) and the FY2025 annual result came in at -$42.0 million, up 30.7% from the prior year.
- EBIT eased to -$14.1 million in Q1 2026 per XLO's latest filing, from -$11.8 million in the prior quarter.
- Over five years, EBIT peaked at -$1.9 million in Q3 2025 and troughed at -$24.6 million in Q2 2022.
- A 5-year average of -$16.8 million and a median of -$17.4 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT dropped 28.47% in 2022, then jumped 86.93% in 2025.
- Over 5 years, EBIT stood at -$23.2 million in 2022, then rose by 21.74% to -$18.1 million in 2023, then advanced by 24.83% to -$13.6 million in 2024, then advanced by 13.16% to -$11.8 million in 2025, then declined by 19.23% to -$14.1 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$14.1 million, -$11.8 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.49 Mn |
| Mar 31, 2026 | -14.11 Mn |
| Dec 31, 2025 | -11.84 Mn |
| Sep 30, 2025 | -1.93 Mn |
| Jun 30, 2025 | -14.37 Mn |
| Mar 31, 2025 | -13.85 Mn |
| Dec 31, 2024 | -13.63 Mn |
| Sep 30, 2024 | -14.76 Mn |
| Jun 30, 2024 | -14.70 Mn |
| Mar 31, 2024 | -17.49 Mn |
| Dec 31, 2023 | -18.13 Mn |
| Sep 30, 2023 | -17.36 Mn |
| Jun 30, 2023 | -20.12 Mn |
| Mar 31, 2023 | -23.53 Mn |
| Dec 31, 2022 | -23.17 Mn |
| Sep 30, 2022 | -20.21 Mn |
| Jun 30, 2022 | -24.55 Mn |
| Mar 31, 2022 | -21.22 Mn |
| Dec 31, 2021 | -19.56 Mn |
| Sep 30, 2021 | -15.96 Mn |